Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).

Citation

• Basch, E. M., Scholz, M. C., De Bono, J. S., Vogelzang, N. J., De Souza, P. L., Marx, G. M., . . . Scher, H. I. (2015). Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. Journal of Clinical Oncology, 33(7_suppl), 141. doi:10.1200/jco.2015.33.7_suppl.141

Digital Object Identifier (doi)

• 10.1200/jco.2015.33.7_suppl.141

Web Of Science Accession Number

Start Page

• 141

End Page

• 141

Volume

• 33

Issue

• 7_suppl

Place Of Publication

Abstract

UOW Authors

•   De Souza, Paul (external author)

Publication Date

• 2015

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Basch, E. M., Scholz, M. C., De Bono, J. S., Vogelzang, N. J., De Souza, P. L., Marx, G. M., . . . Scher, H. I. (2015). Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. Journal of Clinical Oncology, 33(7_suppl), 141. doi:10.1200/jco.2015.33.7_suppl.141

Digital Object Identifier (doi)

• 10.1200/jco.2015.33.7_suppl.141

Web Of Science Accession Number

Start Page

• 141

End Page

• 141

Volume

• 33

Issue

• 7_suppl

Place Of Publication